Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells.
Transport of reduced folates in murine leukemia cells is mediated by the bidirectional reduced folate carrier (RFC1) and independent unidirectional exit pumps. RFC1 has been proposed to be intrinsically equilibrating, generating transmembrane gradients by exchange with inorganic and organic anions. This paper defines the role of high level carrier expression, through transfection with RFC1 cDNA, on concentrative transport of the folate analog, methotrexate (MTX) in murine L1210 leukemia cells. RFC1 was expressed in the MTXrA line, which lacks a functional endogenous carrier to obtain the MTXrA-R16 clonal derivative. Influx was increased approximately 9-fold in MTXrA-R16 cells without a change in Km. The efflux rate constant was increased by a factor of 5.1 relative to L1210 cells, and this resulted in only a 2.1-fold increase in the steady-state level of free intracellular MTX, [MTX]i, when [MTX]e was 1 microM. The concentrative advantage for RFC1 (the ratio of [MTX]i in MTXrA-R16 to L1210 cells) increased from 1.8 at 0.1 microM MTX to 3.8 at an [MTX]e level of 30 microM. Augmented transport in MTXrA-R16 cells was accompanied by a 2-fold increase in accumulation of MTX polyglutamate derivatives and a approximately 50% decrease in the EC50 for 5-formyltetrahydrofolate and folic acid and the MTX IC50 relative to L1210 cells. These alterations paralleled changes in [MTX]i and not the much larger change in influx at low [MTX]e levels, consistent with the critical role that free intracellular folates and drug play in meeting cellular needs for folates and as a determinant of antifolate activity, respectively. The data indicate that RFC1 produces a large and near symmetrical increase in the bidirectional fluxes of MTX resulting in only a small increase in the transmembrane chemical gradient at low extracellular folate levels. Hence, increased expression of RFC1, alone, may not be an efficient adaptive response to folate deprivation, and other factors may come into play to account for the marked increases in concentrative folate transport which occur when cells are subjected to low folate-selective pressure.
Zhao
R
R
Departments of Medicine, Molecular Pharmacology, and the Albert Einstein College of Medicine Cancer Center, Bronx, New York 10461, USA.
Seither
R
R
Brigle
K E
KE
Sharina
I G
IG
Wang
P J
PJ
Goldman
I D
ID
D000818:Animals; D000838:Anions; D001692:Biological Transport; D002352:Carrier Proteins / Q000378:metabolism*; D005492:Folic Acid / Q000378:metabolism; D005575:Formyltetrahydrofolates / Q000378:metabolism; D007939:Leukemia L1210; D008564:Membrane Potentials; D008565:Membrane Proteins / Q000378:metabolism*; D026901:Membrane Transport Proteins; D008727:Methotrexate / Q000378:metabolism*; D051379:Mice; D011099:Polyglutamic Acid / Q000378:metabolism
D000838:Anions; D002352:Carrier Proteins; D005575:Formyltetrahydrofolates; D008565:Membrane Proteins; D026901:Membrane Transport Proteins; C492292:Slc19a2 protein, mouse; D011099:Polyglutamic Acid; D005492:Folic Acid; D008727:Methotrexate